Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related death. Non-alcoholic fatty liver disease (NAFLD) affects a large proportion of the US population and is considered to be a metabolic predisposition to liver cancer 1-5 . However, the role of adaptive immune responses in NAFLD-promoted HCC is largely unknown. Here we show, in mouse models and human samples, that dysregulation of lipid metabolism in NAFLD causes a selective loss of intrahepatic CD4 + but not CD8 + T lymphocytes, leading to accelerated hepatocarcinogenesis. We also demonstrate that CD4 + T lymphocytes have greater mitochondrial mass than CD8 + T lymphocytes and generate higher levels of mitochondrially derived reactive oxygen species (ROS). Disruption of mitochondrial function by linoleic acid, a fatty acid accumulated in NAFLD, causes more oxidative damage than other free fatty acids such as palmitic acid, and mediates selective loss of intrahepatic CD4 + T lymphocytes. In vivo blockade of ROS reversed NAFLD-induced hepatic CD4 + T lymphocyte decrease and delayed NAFLDpromoted HCC. Our results provide an unexpected link between lipid dysregulation and impaired anti-tumour surveillance.
Letter reSeArCH natural killer (NK) T cells (Extended Data Fig. 2d , f), or splenic CD4 + T lymphocytes was observed (Extended Data Fig. 2g ). Unlike CD4 + T lymphocytes, intrahepatic CD8 + T lymphocytes remained unchanged ( Fig. 1e and Extended Data Fig. 2a, b ). The liver-specific reduction of CD4 + but not CD8 + T lymphocytes was also observed in the two other dietary NAFLD models in both tumour-free and tumour-bearing settings (Extended Data Fig. 2h-t) , illustrating a tumour-independent but NAFLD-dependent mechanism. In addition, fewer CD4 + but not CD8 + T lymphocytes were found in leptin-deficient (ob/ob) mice (Extended Data Fig. 2u-x) .
CD4 + T lymphocytes in NAFLD mice were characterized. Higher levels of CD69 and CD44 hi CD62 lo subsets were found in MYC-ON MCD mice (Extended Data Fig. 3a-d ). Hepatic but not splenic CD4 + T lymphocytes also consistently produced more interferon (IFN)-γ but not interleukin (IL)-4 (Extended Data Fig. 3e -g). Although T-bet, GATA3 and Foxp3 frequency did not change, more ROR-γt was detected in MYC-ON MCD mice (Extended Data Fig. 3h ). Accordingly, intrahepatic CD4 + T lymphocytes produced more IL-17 in NAFLD (Extended Data Fig. 3i , j). No change of regulatory T lymphocyte (T reg ) frequency was found, and absolute numbers decreased (Extended Data Fig. 3h , k), consistent with a previous report 17 . In addition, the T reg function remained unchanged in NAFLD (Extended Data Fig. 3l ). Together, our results indicate that NAFLD caused activation of hepatic CD4 + T lymphocytes in mice.
CD4 + T lymphocytes have been reported to inhibit HCC initiation and mediate tumour regression 18, 19 . It has also been reported that a considerable fraction of non-synonymous cancer mutations is immunogenic and that the majority of the immunogenic mutanome is recognized by CD4 + T lymphocytes 20 . Therefore, we studied tumour-specific CD4 + T lymphocytes. α-Fetoprotein (AFP)-specific CD4 + T lymphocytes in MYC-ON MCD mice were detected, suggesting that MYC tumours induced anti-tumour CD4 + T lymphocyte responses (Extended Data Fig. 3m ). Next, we depleted CD4 + T lymphocytes to study their relevance to tumour growth. CD4 antibody depletion (Extended Data Fig. 3n ) caused more hepatic tumour lesions in MYC-ON MCD mice ( Fig. 2a-c) . In control-diet-fed MYC mice, CD4 antibody depletion also promoted tumours but at a later time point (Extended Data Fig. 3o, p) . These results suggested that loss of CD4 + T lymphocytes strongly contributed to HCC development in MYC-ON mice.
Next, we studied CD4 + T lymphocyte survival in mice with NAFLD, and a higher annexin V + level was found in MYC-ON MCD mice than that in MYC-ON mice fed with control diet ( Fig. 3a and Extended Data Fig. 4a ). We hypothesized that the extensive hepatic lipid accumulation induced the CD4 + T lymphocyte loss. Hepatocytes isolated from MYC-ON MCD mice, which showed accumulation of lipid droplets (Extended Data Fig. 4b ), or control mice, were co-cultured with splenocytes. Interestingly, a significant increase in annexin V + 7AAD + cells was seen in CD4 + but not CD8 + T lymphocytes (Extended Data Fig. 4c-e ). No cell-to-cell contact was required ( Fig. 3b ). Higher lipid levels were detected in hepatic CD4 + T lymphocytes in MCD mice (Extended Data Fig. 4f , g). This prompted us to examine whether lipids released from lipid-laden hepatocytes were taken up by CD4 + T lymphocytes and caused cell death. To test this hypothesis, we first measured the hepatic free fatty acid (FFA) composition. Consistent with previous reports, palmitic acid (C16:0), stearic acid (C18:0), linoleic acid (C18:2), arachidonic acid (C20:4) and docosahexaenoic acid (C22:6) are the abundant FFAs ( Fig. 3c and Extended Data Table 1 ). Although the total amount of FFAs did not change significantly (Extended Data Table 1), the levels of C16:0 and C22:6 decreased. C18:2 was the only abundant FFA, which accumulated in the liver after MCD treatment ( Fig. 3c ). Our data are supported by previous reports of hepatic C18:2 accumulation in HF-diet-induced NAFLD mice and ob/ob mice 8, 21 . Next, we depleted FFAs from conditioned hepatocyte-culture medium. As expected, FFA-depleted conditioned medium no longer caused CD4 + T lymphocyte death ( Fig. 3d ). FFAs in conditioned medium from lipid-laden hepatocytes were further analysed, and C16:0, C18:0 and C18:2 were identified as predominant FFAs (Extended Data Fig. 4h , i).
Then, isolated CD4 + T lymphocytes were incubated with individual FFAs to study their effect on cell survival. Comparing other FFAs, C18:2 treatment caused a substantially higher level of 7AAD + annexin V + cells. (Fig. 3e ). Unlike CD4 + T lymphocytes, cell death in CD8 + T lymphocytes was not affected at the tested concentration ( Fig. 3f ). Similar results were found in activated T lymphocytes (Extended Data Fig. 4j ). Dose-response and time-course analysis confirmed that CD4 + T lymphocytes were more susceptible to C18:2-induced cell death than CD8 + T lymphocytes (Extended Data Fig. 4k -m). The increase of caspase 3/7 activity confirmed that CD4 + T lymphocytes died through apoptosis (Extended Data Fig. 4n ). Similar cell death rates between CD4 + and CD8 + T lymphocytes were observed in an H 2 O 2 -induced cell death model, showing that the effect is specific to C18:2 (Extended Data Fig. 4o ). Interestingly, mice fed with a high C18:2 diet showed a reduction in CD4 + but not CD8 + T lymphocytes ( Fig. 3g , h) suggesting that C18:2 is sufficient to cause CD4 + T lymphocyte death in vivo.
The mechanism of how C18:2 induced CD4 + T lymphocyte death was studied. No difference in cellular C18:2 uptake by CD4 + versus CD8 + T lymphocytes was found (Extended Data Fig. 4p ). Direct assessment revealed greater mitochondrial mass in CD4 + lymphocytes (Fig. 4a ). Microarray analysis revealed that oxidative phosphorylation and mitochondrial dysfunction pathways were specifically altered in CD4 + but not CD8 + T lymphocytes after C18:2 treatment (Extended Data Fig. 5 ). CPT1a, the rate-limiting enzyme for importing FFAs into mitochondria, increased in parallel with the decrease of a number of genes coding components for the electron transport complex (Extended Data Fig. 6a ). C18:2 was more potent than other FFAs in upregulating CPT1a (Fig. 4b ). A similar effect was observed in Jurkat cells, a human CD4 + -derived T leukaemia cell line (Extended Data Fig. 6b ). Knockdown of CPT1a rescued Jurkat cells from C18: 2-induced cell death ( Fig. 4c and Extended Data Fig. 6c ). All these results pointed towards mitochondria as the critical mediator for CD4 + T lymphocyte death. Inside mitochondria, FFAs are β-oxidized to fuel ATP generation via the electron transport chain (ETC). Fatty acid oxidation (FAO) was measured, and C18:2 showed a greater FAO rate than C16:0 ( Fig. 4d ). Higher FAO favours more NADH entering the ETC to generate ATP. However, our array data also suggested that C18:2 impaired ETC function (Extended Data Fig. 6a ). Indeed, mitochondrial membrane potential, which is maintained by proper ETC activity, was significantly decreased by C18:2 in CD4 + but not CD8 + T lymphocytes (Fig. 4e) . A disrupted ETC can become a major site Letter reSeArCH of premature electron leakage to oxygen to generate ROS and lead to cell death 22 .
To assess mitochondrial respiration, oxygen consumption analysis was performed. Normalized oxygen consumption rates (OCRs) were significantly higher in CD4 + T lymphocytes compared with CD8 + T lymphocytes, consistent with previous reports 23 . Treatment with oligomycin, an inhibitor of mitochondrial ATP synthase, revealed substantial levels of ATP-synthase-dependent oxygen consumption in both CD4 + and CD8 + T lymphocytes ( Fig. 4f and Extended Data Fig. 6d ). C18:2 abrogated the oligomycin-sensitive fraction of the OCR in CD4 + and CD8 + T lymphocytes without reducing total oxygen consumption levels ( Fig. 4f and Extended Data Fig. 6d ). These data are consistent with a shift in oxygen consumption from ATPsynthase-dependent to ATP-synthase-independent ROS production. In contrast, C16:0 failed to eliminate ATP-synthase-dependent oxygen consumption in CD4 + T lymphocytes ( Fig. 4g and Extended Data Fig. 6e ). Consistently, increased total ROS production was found in CD4 + T lymphocytes when co-cultured with C18:2 versus C16:0 (Extended Data Fig. 6f ). Moreover, elevated ROS levels were detected in hepatic CD4 + T lymphocytes ex vivo under NAFLD conditions (Fig. 4h ) Finally, mitochondrial superoxide was confirmed to increase selectively in CD4 + T lymphocytes after C18:2 treatment (Fig. 4i) , and CPT1a knockdown blocked C18:2-induced mitochondrial ROS production (Extended Data Fig. 6g ). Taken together, these data suggest that greater levels of mitochondrial-derived ROS accumulate in CD4 + T lymphocytes after C18:2 treatment, leading to their depletion.
Therefore, we tested the role of ROS in NAFLD-associated CD4 + T lymphocyte death and HCC development in vivo. Blocking ROS with catalase or N-acetylcysteine (NAC) abrogated cell death in vitro in CD4 + T lymphocytes when incubated with hepatocytes from MCD-ON MYC mice (Fig. 4j) . Similarly, catalase and NAC prevented C18:2-induced CD4 + T lymphocyte death in vitro (Extended Data Fig. 6h ). Oxidative stress is an important factor in NAFLD progression 24 . To test whether ROS mediate hepatic CD4 + T lymphocyte loss in vivo, we treated MCD-diet-fed mice with NAC. Although NAC treatment did not influence steatosis (Extended Data Fig. 6i, j) , it effectively reversed the loss of hepatic CD4 + T lymphocytes (Fig. 4k ). More importantly, NAC treatment significantly delayed NAFLD-promoted tumour development ( Fig. 4l and Extended Data Fig. 6j ). Tumour lesions occurred despite NAC treatment when CD4 + T lymphocytes were removed, suggesting that prevention of CD4 + T lymphocyte death mediates at least partially the anti-tumour effect of NAC. Similar results were obtained using mitoTEMPO 25 , a specific mitochondrial antioxidant in both in vitro and in vivo settings (Fig. 4m-o) .
C18:2 has also been identified as an important fatty acid in the context of NAFLD in humans 26, 27 . We tested whether C18:2 also affects human CD4 + T lymphocyte survival. Consistent with our mouse data, from conditioned medium (n = 3 for none, 9 for other treatments; two-way ANOVA). e, f, Lymphocyte survival after FFA treatment (n = 4, one-way ANOVA). g, h, CD4 + and CD8 + T lymphocytes in high-or low-C18:2-diet-fed mice (n = 5, Student's t-test). All data are mean ± s.e.m. *P < 0.05.
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C18:2, but no other tested FFAs, caused selective CD4 + but not CD8 + T lymphocyte death ( Fig. 4p and Extended Data Fig. 7a ). Similarly, C18:2 but not C16:0 increased the ROS level in human CD4 + T lymphocytes (Extended Data Fig. 7b ). Finally, intrahepatic CD4 + T lymphocytes in liver biopsies from patients with non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH) and viral hepatitis were determined (Extended Data Table 2 ). While ALT and AST levels did not differ among patients with different liver diseases (Extended Data Fig. 7c, d) , fewer CD4 + T lymphocytes were found in NASH and ASH patients than in viral hepatitis patients (Extended Data Figs 7e and 8) , and the CD4/CD8 ratio was significantly lower in NASH patients, supporting the idea of selective CD4 + T lymphocyte loss (Fig. 4q ). 
Interestingly, lower CD4 counts were also found in ASH patients; ASH has very similar histological features to NASH. Dysregulation of lipid metabolism and accumulation of lipids in the liver is part of the aetiology of NAFLD. So far, NASH has been described as causing NF-κB dysregulation, activation of the inflammasome, Toll-like receptor activation and affecting innate immune responses through multiple pathways or directly affecting hepatocytes [28] [29] [30] . Our results extend these findings by describing a novel link between obesity-induced lipid accumulation and selective CD4 + T lymphocyte loss, suggest a critical role for CD4 + T lymphocytes in the disease progression from NAFLD to HCC. ; n = 6 for CDAA and n = 5 mice for CTR, P = 0.0345, Student's t-test. f-i, The effect of the CDAA and HF diet on liver carcinogenesis in diethylnitrosoamine (DEN)-injected C57BL/6 mice. Experimental setup, representative tumour-free H&E stainings, macroscopic liver images and surface tumour counts are shown. Scale bar, 100 μm. Data are mean ± s.e.m.; n = 13 for CTR, n = 9 for HF, n = 10 for CDAA, *P < 0.05, one-way ANOVA.

